Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
or

FS Development Corp II Cl A (FSII)

FS Development Corp II Cl A (FSII)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
9.80 -0.20 (-2.00%) 12/23/21 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 9.80 unch (unch) -
Profile for Thu, Dec 23rd, 2021

Company Info

FS Development Corp II Cl A 900 LARKSPUR LANDING CIRCLE SUITE 150 SAN FRANCISCO CA 94939 USA

P: 415-877-4887

Sector:

Medical

INDUSTRY GROUPING:

Medical - Biomedical

Description:

FS Development Corp. II entered into a definitive business combination agreement with Pardes Biosciences Inc.

Key Statistics

Overview:

Market Capitalization, $K 203,125
Shares Outstanding, K 20,727
Annual Sales, $ 0 K
Annual Net Income, $ 0 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -1,220 K
% of Institutional Shareholders 84.57%
Float, K 20,727
% Float 100.00%

Growth:

1-Year Return -9.18%
3-Year Return 0.00%
5-Year Return 0.00%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 0.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Next Earnings Date 10/16/12
Earnings Per Share ttm 0.00
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

FSII Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % 0.00%
Return-on-Assets % 0.00%
Profit Margin % 0.00%
Debt/Equity 0.00
Price/Sales N/A
Price/Cash Flow N/A
Price/Book N/A
Book Value/Share -0.43
Interest Coverage 0.00
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Value Investing Philosophies: Graham, Buffett, Bogle, and EMH in Perspective